.svg){kind=small}
Mar-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
In Illinois, Avexia has consistently maintained a strong presence in the Capsules and Topical categories, holding steady at the number 2 and 1 spots respectively over the past few months. This demonstrates a robust demand for their products in these categories. However, their performance in Concentrates shows a gradual upward trajectory, moving from 18th in December 2024 to 12th by March 2025, indicating a growing acceptance and increasing market share in this segment. The steady performance in the Topical category, where they remain unchallenged at the top, suggests a strong brand loyalty and product satisfaction among consumers in Illinois.
In Maryland, Avexia's performance in the Capsules category shows a commendable rise, jumping from 5th place in December 2024 to consistently holding the 2nd spot from January 2025 onwards. This upward movement highlights a significant competitive edge in this category. Conversely, their absence from the top 30 in the Concentrates category since February 2025 could be a point of concern, indicating a potential decline in consumer interest or increased competition. Meanwhile, in New Jersey, Avexia has maintained a dominant position in the Tincture & Sublingual and Topical categories, consistently ranking 1st, which underscores their strong market presence and consumer preference in these segments.
Competitive Landscape
In the Illinois topical cannabis market, Avexia has consistently maintained its top position from December 2024 through March 2025, demonstrating strong brand loyalty and market presence. Despite a noticeable decline in sales from December to February, Avexia's sales rebounded in March, indicating effective strategies to counteract market fluctuations. Meanwhile, Nature's Grace and Wellness and Doctor Solomon's have been vying for the second and third ranks, with Nature's Grace and Wellness experiencing a drop out of the top three in February. This competitive dynamic highlights Avexia's robust positioning and ability to sustain its leadership amidst fluctuating sales and competitive pressures in the Illinois market.
Notable Products
In March 2025, Avexia's top-performing product was the CBD/THC 1:1 Harmony Pain Relief Balm (100mg CBD, 100mg THC, 2oz) in the Topical category, maintaining its first-place ranking with sales of $14,728. The CBD/THC 4:1 Relief Tablets 40-Pack (400mg CBD, 100mg THC) in the Capsules category also held steady in second place, showing a positive sales trend from previous months. The CBN/CBD/THC 1:1:1 Comfort Tablets 40-Pack (100mg CBN, 100mg CBD, 100mg THC) ranked third, though its sales slightly declined compared to February. The CBD/THC 1:1 Harmony Micro-Dosed Tablets 40-Pack (100mg CBD, 100mg THC) improved its position to fourth, recovering from a dip in January. The CBG/THC 1:1 Ascend Tablets 40-Pack (100mg CBG, 100mg THC) remained in fifth place, showing consistent performance since its introduction.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
